Key findings indicate that BM remains a significant challenge for prostate cancer patients, with its risk strongly correlated with elevated alkaline phosphatase (ALP) levels, larger tumor sizes, higher Gleason scores, extraprostatic extension (ECE) invasion, and increased prostate-specific antigen (PSA) levels both preoperatively and postoperatively. The gene discussed is KLK3; the disease is prostate cancer.